Universitair Medisch Centrum Groningen — Sponsor Intelligence | 70 EU Trials

Filter these 70 trials by condition, phase, country and more.

Open in Search →

70 Registered trials

36 Recruiting

18 Completed trials

10 Countries active

88 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase I

Phase III: 10 Phase II/III: 1 Phase II: 20 Phase I/II: 5 Phase III/IV: 3 Phase IV: 14 Phase I: 8 Phase I (Other): 5 Phase I (FiH): 4

Oversight events:

1 temporary halt 1 corrective measure across 2 trials

View oversight register →

100%

18 of 18 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Rectal cancer 1 Albuminuria 1 Glioblastoma 1 Polymyalgia rheumatica 1 Giant cell arteritis 1 Endometrial cancer 1 Polycystic liver disease 1 Chronic kidney disease 1 Inflammatory bowel disease 1

Top IMPs

(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 4 FINERENONE 3 ADALIMUMAB 2 ATEZOLIZUMAB 2 BEVACIZUMAB 2 EMPAGLIFLOZIN 2 EVEROLIMUS 2 IOHEXOL 2 MYCOPHENOLATE MOFETIL 2 PEMBROLIZUMAB 2 RISANKIZUMAB 2 TACROLIMUS 2

All trials

70 total

RATE: Reduced anticoagulation targets in extracorporeal life support Pending

2023-509675-16-01 Phase III 1 country
RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis Pending

2024-510926-19-00 Phase II 1 country
[18F]-olaparib PET; Molecular imaging of DNA damage response by [18F]-olaparib PET Pending

2024-511962-34-00 Phase I (FiH) 1 country OLAPARIB
FAPI-PET for GPSD Pending

2024-511977-31-01 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
i-Care; Quantitative-imaging in cardiac transthyretin amyloidosis Pending

2024-513310-36-01 Phase IV 1 country IODINE (123I) IOBENGUANE; SODIUM FLUORIDE (18F)
Targeted fluorescence endoscopy for detection of the primary cancer lesion in patients with a metastasis of unknown primary tumor in the hea… Pending

2024-513897-23-00 Phase II 1 country CETUXIMAB
AliCsa; Efficacy of oral alitretinoin versus oral cyclosporine in patients with moderate to very severe hand eczema. A randomized prospecti… Pending

2024-515140-23-00 Phase IV 1 country
RESET-TRD; a Randomised trial on oral ESketamine compared to Electroconvulsive Therapy for patients with Treatment Resistant Depression Pending

2024-517485-42-00 Phase III 1 country ESKETAMINE
Randomized controlled trial comparing immediate versus extended release tacrolimus; reducing calcineurin inhibitor related toxicity in lung … Pending

2024-518639-12-00 Phase III 1 country TACROLIMUS
Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease Pending

2024-518865-85-00 Phase II 1 country [18F]MC225
GRoningen Early-PD Ambroxol Treatment Pharmacokinetics Pending

2024-519088-16-01 Phase I (Other) 1 country
Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer: Clinical Validation Pending

2025-522027-95-00 Phase III 1 country
CANagliflozin In DIAlysis Patients Pending

2025-522742-46-00 Phase IV 1 country [18F] CANAGLIFLOZIN; CANAGLIFLOZIN
PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer Pending

2025-522883-34-00 Phase IV 1 country BEVACIZUMAB; PEMBROLIZUMAB
GRAIN, Prospective Pilot Study Pending

2025-524470-41-00 Phase I 1 country
A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multip… Pending

2025-524876-43-00 Phase III 1 country AUTOLOGOUS GENETICALLY MODIFIED T LYMPHOCYTES TRANSDUCED WITH LENTIVIRUS EXPRESS…
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD) Pending

2025-525068-13-00 Phase II 3 countries BI 456906; SURVODUTIDE
IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment o… Recruiting

2024-510924-38-00 Phase II 1 country
[68Ga]FAPI PET/CT to detect fibroblast activity in pulmonary COVID patients with and without long-term health problems. Recruiting

2024-517931-29-00 Phase III/IV 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC) Recruiting

2023-506886-76-00 Phase IV 2 countries ALECTINIB
Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory… Recruiting

2025-521420-30-00 Phase I/II 1 country ADALIMUMAB; RISANKIZUMAB
Dual-Wavelength Quantitative Fluorescence Endoscopy for Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer: A Phase I Mult… Recruiting

2024-520090-12-00 Phase I 1 country
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS) Recruiting

2025-523743-35-00 Phase II 1 country BI 690517; EMPAGLIFLOZIN; IOHEXOL; SPIRONOLACTONE
A phase I study investigating the local tolerability and pharmacokinetics of isoniazid (INH) inhalation by wet nebulization in patients with… Recruiting

2024-517793-25-00 Phase I 1 country

Showing 1–24 of 70 trials

← All sponsors A–Z